

**The Hospital for Sick Children  
Technology Assessment at SickKids (TASK)**

**SUPPLEMENT**

**Updated**

**A MICROCOSTING AND COST-CONSEQUENCE ANALYSIS OF GENOMIC TESTING  
STRATEGIES IN CHILDREN WITH CONGENITAL ANOMALIES AND  
DEVELOPMENTAL DELAY**

Authors:

Kate Tsiplova, MSc

Research Project Manager, Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,  
Canada

Richard M. Zur, PhD

Research Project Manager, Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto,  
Canada

Wendy J. Ungar, MSc, PhD

Senior Scientist, Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada  
Professor, Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada

**Report No. 2016-02.2**

**Date: September 21, 2016**

Co-investigators:

Christian R. Marshall, PhD

Associate Director, Genome Diagnostics, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada

Assistant Professor, Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada

Dimitri J. Stavropoulos, PhD

Co-Director, Cytogenetics, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada

Assistant Professor, Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada

Sergio Pereira, PhD

Manager, The Centre for Applied Genomics, Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada

Daniele Merico, PhD

Facility Manager, The Centre for Applied Genomics, Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada

Ted Young, PhD

Laboratory Specialist, Cytogenetics, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada

Wilson W.L. Sung, MSc

Bioinformatics Analyst, The Centre for Applied Genomics, Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada

Stephen W. Scherer, PhD

Director, The Centre for Applied Genomics, Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada

Professor of Medicine, Department of Molecular Genetics, University of Toronto, Toronto, Canada

**Acknowledgements:**

This research was supported by a Large-Scale Applied Research Project grant from Genome Canada and the Ontario Genomics Institute. We thank the following individuals who provided assistance with obtaining re and price data: Team Lead with the Cytogenetics, The Department of Paediatric Laboratory Medicine, Mary Shago, Co-Director with the Cytogenetics, The Department of Paediatric Laboratory Medicine and Manager, Decision Support at The Hospital for Sick Children and Kelly Hogan at the Canadian Institute for Health Information. We thank Pooyeh Graili for reviewing the microcosting models. We also wish to thank Dr. Robin Hayeems, PhD, The Hospital for Sick Children, for valuable feedback.

## Background and assumptions

In this supplemental analysis, sample and program costs and the incremental cost to incremental diagnostic yield ratios were calculated for children with congenital anomalies (CA) and developmental delay (DD). Developmental delay may include autism spectrum disorder (ASD). In contrast to a target population approach used in the report, this analysis assumes a more heterogeneous group of children in a centralized clinic approach. These patients may present with a developmental delay phenotype but have not yet received a clinical diagnosis.

The model assumptions that were made to determine cost per DD/CA sample and 5-year program costs for CMA, WES and WGS are listed in Table 1. For CMA, the average total number of tests done per year in the institution for all indications was 3948, based on the 2013/14 fiscal year. Of these, 79.6% of all CMA tests were conducted for patients with developmental delay (Stavropoulos, DJ, personal communication). It was assumed that the maximum number of WES/WGS tests done per year in the institution for all indications was 1000 and that 79.6% (796) of these tests would be conducted for developmental delay.

The diagnostic yields of WGS and CMA for children with congenital anomalies and developmental delay were obtained from Stavropoulos *et al.* (2016) (1). In the study, 100 paediatric patients were offered CMA and WGS. The diagnostic yield was estimated to be 8% for CMA only and 34% for WGS. No study with a similar population that measured the diagnostic yield of CMA combined with WES was found. Therefore, the only clinical scenario considered was WGS vs. CMA.

Table 1. Inputs for analysis for children with congenital malformations and developmental delay

	CMA	WES	WGS, HiSeq® 2500	WGS, HiSeq X™
Total tests performed on large or small equipment per year (including condition of interest)	3948	1000	1000	1000
Proportion of all tests for indicated condition	79.62%	79.62%	79.62%	79.62%
Number of disease tests performed per year	3143	796	796	796
Number of primary variants per test (WES, WGS)		2	2	2
Diagnostic yield of test	0.08	N/A	0.34	0.34

Abbreviations: CMA, Chromosomal microarray analysis; WES, Whole exome sequencing; WGS, Whole genome sequencing.

## Summary of costs for children with developmental delay or congenital anomalies

The mean total costs per sample for CMA, WES, WGS (HiSeq® 2500) and WGS (HiSeq X™) for Year 1 of a 5-year testing service are shown in Table 2. The annual cost of CMA per DD/CA sample was \$744 (95% CI: 715, 773). The annual cost per DD/CA sample of WES was \$1412 (95% CI: 1372, 1452). The annual cost per DD/CA sample of WGS was \$5275 (95% CI: 5007, 5538) conducted on HiSeq® 2500 and \$2488 (95% CI: 2395, 2580) conducted on HiSeq X™.

Table 2. Estimated annual cost per DD/CA sample for CMA, WES and WGS.


Cost Category	CMA (95% CI)	WES (95% CI)	WGS, HiSeq® 2500 (95% CI)	WGS, HiSeq X™™ (95% CI)
Labour	141.5 (132.4, 150.8)	318.3 (294.2, 342)	518.1 (467.9, 570)	251 (226.2, 275.2)
Large Equipment	30 (28.1, 31.9)	192.8 (185.2, 200.6)	192.8 (184.8, 200.3)	292 (275.2, 309)
Small Equipment	434.4 (409.7, 460.3)	4.4 (4.3, 4.6)	4.4 (4.3, 4.6)	4.4 (4.3, 4.6)
Supplies	98.1 (89, 107.6)	657.7 (634, 681.5)	4065.3 (3806, 4322.5)	1381 (1298, 1460.6)
Follow-up	141.5 (132.4, 150.8)	112.2 (103.7, 120.8)	178.6 (163.7, 194.3)	178.7 (163.6, 195)
Bioinformatics	N/A	6.7 (6, 7.5)	123.4 (108, 139)	207.5 (190.1, 225.4)
Overhead	39.5 (37.3, 41.6)	120.1 (114.3, 125.9)	192.9 (180.6, 205.3)	173.6 (165.7, 181.6)
<b>Total</b>	<b>743.6</b> <b>(714.7, 772.9)</b>	<b>1412.2</b> <b>(1372.3, 1452.2)</b>	<b>5275.4</b> <b>(5007.2, 5538.1)</b>	<b>2488.3</b> <b>(2394.9, 2580.1)</b>

Estimates are given in 2015 Canadian dollars (CAD) for year 1 of a 5-year program. Confidence intervals (CI) are based on 10000 Monte Carlo replications. Results are based on overhead costs of 23%; 3948 CMA, 1000 WES and 1000 WGS tests for all indications per year; and two primary variants found per WES/WGS test.

Abbreviations: DD, Developmental delay; CA, Congenital anomalies; CMA, Chromosomal microarray analysis; WES, Whole exome sequencing; WGS, Whole genome sequencing.

The total program cost to offer CMA for DD/CA diagnosis over five years was \$11.0 million (95% CI: 10.6, 11.4). The five-year program costs of CGES for DD/CA were \$5.26 million (95% CI: 5.11, 5.41) for WES, \$19.8 million (95% CI: 18.8, 20.8) for WGS on HiSeq® 2500 and \$9.28 million (95% CI: 8.93, 9.62) for WGS on HiSeq X™. Figure 1 shows the present value of program costs for each major cost category and for each test.

Figure 1. Present value of DD/CA program costs over five years for CMA, WES and WGS.



Estimates are given in 2015 Canadian dollars (CAD). Confidence bands are based on 10000 Monte Carlo replications. Program costs are based on 3143 CMA tests and 796 WES/WGS tests done annually at the institution.

Abbreviations: DD, Developmental delay; CA, Congenital anomalies; CMA, Chromosomal microarray analysis; WES, Whole exome sequencing; WGS, Whole genome sequencing

## Cost-Consequence Analysis for children with MCA or DD

For WGS (HiSeq® 2500) vs. CMA, the incremental cost to diagnostic yield ratio was \$17430 in Year 1 of the five-year program. The incremental cost per additional patient with a positive finding was reduced by more than half if WGS is performed on the HiSeq X™ platform, to \$6710 (Table 3).

Table 3. Estimated total annual incremental cost per DD/CA sample, estimated incremental diagnostic yield and estimated incremental cost per additional patient with a positive finding, Year 1

Scenario	Incremental sample cost (CAD) (95% CI)	Incremental diagnostic yield (diagnosis rate)	Incremental ratio (CAD/diagnosis rate)
2. WGS vs. CMA			
2.1 WGS (HiSeq® 2500) vs. CMA	4531.8 (4260.6, 4796.8)	0.26	17430.0
2.2 WGS (HiSeq X™) vs. CMA	1744.8 (1646.7, 1841.4)	0.26	6710.4

Estimates are given in 2015 Canadian dollars (CAD). Confidence intervals (CI) for incremental cost are based on 10000 Monte Carlo replications.

Abbreviations: DD, Developmental delay; CA, Congenital anomalies; CMA, Chromosomal microarray analysis; WES, Whole exome sequencing; WGS, Whole genome sequencing.

## Bibliography

1. Stavropoulos DJ, Merico D, Jobling R, Bowdin S, Monfared N, Thiruvahindrapuram B, et al. Whole-genome sequencing expands diagnostic utility and improves clinical management in paediatric medicine. *Npj Genomic Medicine*. 2016;1(15012).